Duloxetine in the treatment of stress urinary incontinence.

Abstract

This manuscript reviews the pharmacodynamics and pharmacokinetics of duloxetine and its efficacy and safety in women with stress urinary incontinence. Duloxetine is a selective inhibitor of neuronal serotonin and norepinephrine uptake which increases urethral striated muscle activity and bladder capacity. Duloxetine is readily absorbed and extensively metabolized; cytochrome P450 1A2 (CYP1A2) inhibiting drugs can markedly increase duloxetine exposure. The clinical efficacy of duloxetine has consistently been demonstrated in several randomized, double-blind studies in women with moderate-to-severe stress urinary incontinence, but the additional benefit relative to placebo was moderate. Duloxetine treatment is frequently associated with adverse events such as nausea, dry mouth, fatigue, insomnia and constipation, but serious adverse events are rare. Therefore, duloxetine appears suitable for the treatment of stress urinary incontinence.

• Authors: Martin C Michel, Matthias Oelke
• Journal: Women's health (London, England) (Womens Health (Lond)) Vol. 1 Issue 3 Pg. 345-58 (Nov 2005) ISSN: 1745-5065 [Electronic] United States
• PMID: 19803876 (Publication Type: Journal Article)